Biodefense Market Report Scope & Overview:

The Biodefense Market was valued at USD 17.70 Billion in 2025 and is expected to reach USD 29.17 Billion by 2035, growing at a CAGR of 5.11% from 2026 to 2035.

The global biodefense industry is experiencing significant growth owing to rising risks of bioterrorism attacks, increased spending on national preparedness programs by the government, and innovations in pathogen detection techniques. Biodefense consists of an array of processes, goods, and technology aimed at ensuring protection of human health, national security, and global stability from biological agents such as bacteria, viruses, toxins, and engineered microorganisms which may be used as weapons or released intentionally and unintentionally.

The industry comprises vaccines and drugs for protecting against priority biological threats, biodefense detection systems and devices, personal protective equipment for first responders and military forces, and decontamination technologies used in military, civilian emergency response, and public health areas. Government expenditure constitutes more than 70% of the total spending on biodefense, while the procurement landscape in biodefense consists mainly of the following BARDA, the U.S. Department of Defense, and strategic national stockpile program of leading nations.

In June 2025, Emergent BioSolutions received U.S. FDA approval for its next-generation anthrax vaccine with enhanced immunogenicity and a reduced dosing schedule for rapid deployment, substantially improving the clinical utility of anthrax pre-exposure prophylaxis for first responders and military personnel whose operational scenarios require rapid protection establishment before potential anthrax exposure events.

Market Size and Forecast:

• Market Size in 2026E: USD 18.60 Billion

• Market Size by 2035: USD 29.17 Billion

• CAGR: 5.11% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America (43% share)

Biodefense Market Trends:

• Growing adoption of mRNA vaccine platforms is enabling faster development of countermeasures against emerging biological threats.

• AI and machine learning technologies are improving bio surveillance, outbreak prediction, and threat detection capabilities.

• Demand for portable and field-deployable biothreat detection systems is increasing for military and emergency response applications.

• Rising concerns over antibiotic-resistant biothreat agents are driving investment in next-generation therapeutics, monoclonal antibodies, and antitoxins.

• Expanding international biodefense collaborations are supporting investments in bio surveillance, preparedness, response systems, and medical countermeasure stockpiles.

U.S. Biodefense Market Outlook:

The U.S. Biodefense Market was valued at approximately USD 10.70 Billion in 2025 and is expected to reach approximately USD 16.35 Billion by 2035, growing at a CAGR of approximately 4.34%.

The United States of America is the largest commercially oriented biodefense market that has unmatched devotion to ensuring its health security and ability to respond swiftly. The U.S. Government Accountability Office's Project BioShield mandate, the Strategic National Stockpile medical countermeasure procurement program, the Department of Defense's Medical Countermeasure Systems program, and the CDC's public health emergency preparedness program together form the most commercially focused biodefense procurement environment in the world. Emergent BioSolutions' BioThrax anthrax vaccine and CYFENDUS post-exposure prophylaxis, SIGA Technologies' TPOXX smallpox antiviral drug, and Bavarian Nordic's JYNNEOS smallpox and monkeypox vaccine together form the medical countermeasure procurement priorities of the Strategic National Stockpile.

In July 2024, Emergent BioSolutions received FDA approval for CYFENDUS, previously known as AV7909 anthrax vaccine adsorbed adjuvanted, for post-exposure prophylaxis of anthrax disease in adults. The approval creates a new clinical context for anthrax medical countermeasure use following confirmed or suspected exposure, supplementing the pre-exposure prophylaxis application of BioThrax and creating a more comprehensive anthrax defense portfolio that addresses both pre-exposure prevention and post-exposure therapeutic response scenarios.

Biodefense Market Segment Analysis:

• By Product, the Anthrax Countermeasures segment dominated the biodefense market with approximately 32.6% share in 2025, while the Others segment encompassing countermeasures for emerging and engineered biothreats is the fastest growing as the growing concern over novel engineered pathogens.

• By Type, the Vaccines segment dominated the biodefense market with the largest revenue share in 2025, while the Diagnostics and Detection Devices segment is the fastest growing as field-deployable biothreat identification technology.

• By Application, the Military segment dominated the biodefense market with approximately 60% share in 2025, while the Civilian segment is the fastest growing as growing biosecurity awareness.

• By End User, the Hospitals and Clinics segment dominated the biodefense market with approximately 27% share in 2025, while the Pharmaceutical and Biotech Companies segment is the fastest growing as government contract funding for biodefense product development.

By Product, anthrax dominates, emerging biothreats grow fastest

Anthrax countermeasures continued to be the leading product segment accounting for about 32.6% of the total biodefense market in 2025. Anthrax dominance as the most successful biodefense product can be attributed to the fact that anthrax is the topmost priority category A biothreat agent owing to its potential weaponization through aerosol dispersion, robust environmental resistance, and fatality on inhalation. The 2001 anthrax letter attack resulting in five deaths and seventeen people admitted to hospitals created a lasting memory in the biodefense sector of the U.S., ensuring regular purchase of anthrax countermeasures through each annual cycle of BARDA budgets.

The Others category consisting of engineered and emerging biothreats is the fastest-growing category of products due to increasing concerns over bioengineered pathogens and novel zoonotic pathogens spilling over to humans with pandemic potential and the fact that WHO has documented over 14 outbreaks of biological threats in 2023.

By Application, military dominates, civilian grows fastest

The military application continued to lead the market, capturing around 60% of biodefense spending in 2025. This was due to the U.S. Department of Defense’s role as the largest procurement body in the biodefense space across the globe where its medical countermeasure procurement and biological threat detection capabilities and responses have made a significant contribution to the market’s concentration on the military application spending.

The civilian application is the most rapidly growing sector since the impact of the COVID-19 pandemic on political perceptions regarding the need for pandemic preparedness among civilians has permanently raised government spending on civilian biodefense infrastructure above the pre-COVID-19 level. Every government increasing its spending on public health emergencies following the COVID-19 pandemic will add civilian biodefense spending on surveillance systems, medical countermeasures, and public health responses to the existing security-oriented motive of biothreat preparation.

Regional Analysis:

North America Biodefense Market Insights

The global biodefense market was dominated by North America, accounting for around 43% of the revenue share in 2025 owing to the presence of outstanding governmental spending through BARDA, the Strategic National Stockpile, and the Department of Defense that together create the most commercially focused biological threat preparation program in the world through biodefense purchases. The United States accounted for around 87.4% of the North American revenue through Emergent BioSolutions, SIGA Technologies, U.S. operations of Bavarian Nordic and BARDA contracted developing biodefense products.

Canada contributed around 12.6% to the North American revenue share through Public Health Agency of Canada's National Emergency Strategic Stockpile, bio-threat research at the National Microbiology Laboratory and biological incident response capability spending at the Department of National Defence.

Europe Biodefense Market Insights

Europe is an advanced biodefense market with the EU's HERA (Health Emergency Preparedness and Response Authority), the bio surveillance mission at the European Centre for Disease Prevention and Control, and the defense biodefense programs in individual member states generating demand in structured institutions. Germany contributes 22.3% of revenue in Europe via its Bundeswehr biodefense procurement, the bio surveillance activities at the Robert Koch Institute, and the medical countermeasure stockpiles of the Federal Office of Civil Protection and Disaster Assistance.

The United Kingdom, France, and Sweden are key secondary markets with the biodefense research done by DSTL Porton Down, the CBRN protection investments made by the French Directorate General of Armaments, and the headquarters of Bavarian Nordic at Denmark driving commercial biodefense activities in Europe. The cooperation between Bavarian Nordic's JYNNEOS smallpox and monkeypox vaccine program and BARDA reflects the commercial biodefense relationship across the Atlantic Ocean.

Asia Pacific Biodefense Market Insights

The fastest-growing regional market for biodefense in Asia Pacific is supported by China’s biodefence investment amounting to USD 3.2 billion in the country launched in 2023, biodefence awareness and defense research investment in India, Japan’s advanced bio-threat detection capabilities, CBRN defense capability in South Korea, and increased pandemic preparedness investments in the ASEAN region. China contributes to about 44.8% of revenues in Asia Pacific owing to the country's national biosecurity investment, PLA's biodefense capability investment, and pandemic preparedness infrastructure development by the government.

India is considered the most commercially vibrant emerging market in the Asia Pacific region because of the Defence Research and Development Organization’s biological defense program, biodefence contract opportunities in the domestic pharmaceutical and biotechnology sectors, and pandemic preparedness investment made by the government due to the coronavirus pandemic.

MEA & Latin America Biodefense Market Insights

Israel leads MEA revenues at approximately 28.4% through its advanced CBRN defense capability, the Israel Defence Forces’ biological threat preparedness investment, and the IIBR's (Israel Institute for Biological Research) vaccine and therapeutic development programme. Saudi Arabia's Vision 2030 healthcare security investment and Egypt's NAMRU-3 biological research presence add complementary regional demand. Brazil leads Latin American revenues at approximately 44.2% through its CBRN defense infrastructure, the Fiocruz Institute's vaccine development capacity, and the Ministry of Health's biodefense preparedness investment. Mexico and Argentina collectively sustain regional market development through 2035.

Market Dynamics:

Growth Drivers: Geopolitical bioterrorism threat escalation and pandemic preparedness investment sustaining government biodefense commitment

Geopolitical threat escalation's effects on the perception of bioterrorism risk present the biodefense market with its commercially most certain structural growth dynamic. State-sponsoring research of biological nature by adversarial countries, interest of non-state actors in the development of biological weapons, and the demonstration of the extraordinary economic and social impacts of biological events via COVID-19 create political incentives for biodefense investment by governments that go beyond the interests of particular administrations.

The commitment to invest in biodefense over the next five years’ worth USD 88.2 billion by the US government and the establishment of the biosecurity programme for USD 3.2 billion in 2023 by China illustrate the extraordinarily large amount of government biodefense procurement incentives that facilitate market growth regardless of commercial demand dynamics.

Pandemic preparedness investment after the coronavirus pandemic has permanently raised the level of the importance and volume of biodefense infrastructure investment by governments which used to focus their biodefense investments only in military and defense contexts. Every national pandemic preparedness plan that entails a medical countermeasure stockpile for new biological risks creates procurement ties with biodefense product manufacturers, the commercial volume of which globally sustains the market growth in the forecast period.

Restraints: Unpredictable demand patterns and high product development costs creating commercial uncertainty

Unpredictable biological threat occurrence results in demand uncertainty that poses challenges for the commercial planning of biodefense product developers because most of their income comes from government procurement contracts, whose renewal and scaling are determined by government budget appropriation process every year and can depend on threat assessment, political cycles, and other priorities. Every year that the government budget cuts biodefense budget in comparison with previous year leads to the uncertainty of income of the product supplier that has high fixed costs.

High cost and long-time of biodefense product development, including five to fifteen years of development of a new vaccine or therapeutic agent that might cost from one hundred million dollars to five hundred million dollars, pose great commercial risk that prevents many companies from investing into it without government contract.

Opportunities: mRNA-based biodefense vaccine development and broad-spectrum countermeasure platforms

The use of the mRNA vaccine platform for biodefense countermeasure applications is the most commercially transformational short term opportunity due to the ability to rapidly design antigens and therefore develop vaccines on a timeline of weeks rather than the years necessary in traditional recombinant protein or live-attenuated vaccine platforms. Every new biothreat agent for which an mRNA vaccine can be developed in the outbreak response window provides a qualitatively better rapid response solution that ensures high procurement rates for those companies able to produce such vaccines. The Phase III mRNA vaccine programme against multiple biothreat agents at Moderna illustrates the materialization of this opportunity commercially.

Development of the broad-spectrum countermeasure platform is the most commercially scalable opportunity because a single agent that is effective against multiple biothreats provides a commercial advantage that pathogen-specific single agents cannot achieve. Every new broad-spectrum antiviral or immunostimulatory agent that demonstrates efficacy against multiple Category A and B biothreat agents provides a case for stockpiling that amplifies per agent procurement rationale.

Recent Developments:

• 2025: Emergent BioSolutions received FDA approval for its next-generation anthrax vaccine in June 2025 with enhanced immunogenicity and a reduced dosing schedule enabling rapid protection establishment for first responders and military personnel facing potential anthrax exposure scenarios.

• 2025: Bavarian Nordic announced a strategic partnership with BARDA in May 2025 to develop and commercialize a combined smallpox and monkeypox vaccine targeting rising orthopoxvirus threats globally and expanding the JYNNEOS vaccine's commercial application beyond emergency stockpiling into broader public health immunization contexts.

• 2025: SIGA Technologies expanded manufacturing capacity for TPOXX antiviral drug in April 2025, securing new government contracts for additional strategic national stockpile procurement to address increasing biodefense stockpile demand for smallpox antiviral medical countermeasures.

Biodefense Market Key Players:

• Emergent BioSolutions Inc.

• SIGA Technologies Inc.

• Bavarian Nordic AS

• Dynavax Technologies Corporation

• Altimmune Inc.

• XOMA Corporation

• Ichor Medical Systems Inc.

• DynPort Vaccine Company LLC

• Cleveland BioLabs Inc.

• Ology Biosciences Inc.

• Alnylam Pharmaceuticals Inc.

• Soligenix Inc.

• Chimerix Inc.

• National Resilience Inc.

• PharmAthene Inc. (SIGA)

• Pluristem Therapeutics Inc.

• Acurx Pharmaceuticals Inc.

• GlaxoSmithKline plc

• Sanofi SA

• Takeda Pharmaceutical Company Ltd.

Biodefense Market Report Scope: